Health Care & Life Sciences » Biotechnology | Organovo Holdings Inc.

Organovo Holdings Inc. | Balance Sheet

Fiscal year is April-March. All values USD Thousands.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
48,167.00
50,142.00
62,091.00
62,751.00
43,726.00
36,477
Total Accounts Receivable
-
-
259.00
647.00
1,028.00
558
Inventories
63.00
66.00
334.00
550.00
842.00
490
Other Current Assets
891.00
1,054.00
968.00
1,144.00
1,164.00
1,049
Total Current Assets
49,121.00
51,262.00
63,652.00
65,092.00
46,760.00
38,574
Net Property, Plant & Equipment
857.00
2,042.00
3,711.00
3,840.00
2,788.00
1,832
Total Investments and Advances
79.00
79.00
79.00
127.00
127.00
79
Intangible Assets
89.00
80.00
105.00
95.00
151.00
137
Other Assets
40.00
26.00
29.00
26.00
1.00
1
Total Assets
50,186.00
53,489.00
67,576.00
69,180.00
49,827.00
40,623
ST Debt & Current Portion LT Debt
10.00
5.00
-
-
-
Accounts Payable
326.00
1,387.00
787.00
1,171.00
464.00
Other Current Liabilities
1,557.00
3,369.00
3,703.00
4,840.00
4,194.00
Total Current Liabilities
1,893.00
4,761.00
4,490.00
6,011.00
4,658.00
Long-Term Debt
5.00
-
-
-
-
Other Liabilities
4.00
32.00
905.00
807.00
583.00
Total Liabilities
1,902.00
4,793.00
5,395.00
6,818.00
5,241.00
Common Equity (Total)
48,284.00
48,696.00
62,181.00
62,362.00
44,586.00
Total Shareholders' Equity
48,284.00
48,696.00
62,181.00
62,362.00
44,586.00
Total Equity
48,284.00
48,696.00
62,181.00
62,362.00
44,586.00
Liabilities & Shareholders' Equity
50,186.00
53,489.00
67,576.00
69,180.00
49,827.00

About Organovo Holdings

View Profile
Address
6275 Nancy Ridge Drive
San Diego California 92121
United States
Employees -
Website http://www.organovo.com
Updated 07/08/2019
Organovo Holdings, Inc. is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions.